Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Lymphoid 2Gastrointestinal 2Breast 2Tumor-Agnostic 1Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 69Nivolumab 57Ipilimumab 36Specimen Handling 32Magnetic Resonance Spectroscopy 25Cyclophosphamide 22Biopsy 18cemiplimab 14fludarabine 13relatlimab 11binimetinib 11Opdualag 11CTLA-4 Antigen 11trametinib 10fludarabine phosphate 10Radiosurgery 10avelumab 9lifileucel 8dabrafenib 8Radiotherapy 8atezolizumab 7aldesleukin 7Paclitaxel 7Blood Specimen Collection 7encorafenib 6X-Rays 6Standard of Care 6Interleukin-2 6Immunoglobulin G 6HhAntag691 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Itraconazole × Dermatologic × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡